LONDON and NEW YORK, Jan. 27, 2021 /PRNewswire/ — Huma is a digital health company that has distinguished itself during Covid-19 with large-scale, national deployments of ‘hospitals at home[1]’ in the UK’s NHS, Germany and UAE that can double clinical capacity[2] for patients.
The company is driving a digital revolution in care and research, and its technology supports virtual clinical trials[3], remote patient monitoring[4] and ‘hospitals at home’[5]. A growing library of clinically-validated predictive algorithms and digital biomarkers allows clinicians, patients and researchers to collect huge volumes of data and insights through a smartphone or connected device.
Huma might be the only digital health company with multiple national contracts. The company operates across both care and research, working with universities, contract research organizations (CROs), and life science companies to deliver decentralized clinical trials. In 2020, Huma completed a virtual clinical study for patients with atrial-fibrillation, working with
Full story available on Benzinga.com
